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Summary 
This study aims to examine the effect produced by resveratrol on markers of chronic 
systemic inflammation in patients with coronary artery disease (CAD) and 
concomitant autoimmune thyroiditis (Hashimoto's thyroiditis).The study enrolled 85 
patients with coronary artery disease: stable exertional angina, class II, 30 of them 
were found out to have diagnosis of autoimmune thyroiditis (AIT) in its euthyroid 
state (experimental group), 55 patients made up the control group. In a month of 
CAD stabilization therapy (β-blockers, statins, aspirin), the levels of interleukin-1β 
(IL-1β), IL-10, tumor necrosis factor (TNF-α) and expression of mRNA inhibitor of 
kappa B gene (IkB)  nuclear factor kB (NF-kB) transcription were measured in the 
blood of the patients. Then, the experimental group was additionally prescribed to 
take resveratrol in a dose of 100 mg per day.  In 2 months since the beginning of the 
therapy including resveratrol the patients underwent re-examination. The patients 
with CAD and AIT comorbidity were found to have increased levels of IL-1β and 
TNF-α, moderate increase in IL-10. The findings obtained did not significantly differ 
from the data from those in the control group. Expression of mRNA IkB was 
identical in both groups. Under the influence of resveratrol in the patients of the 
experimental group the levels IL-1β and TNF-α were significantly decreased, the 
level of IL-10 was unchanged, and the expression of mRNA IkBα decreased (p 
<0,05). All these findings of the control group stayed unchanged. The results of the 
study demonstrate the anti-inflammatory properties of resveratrol in cases of CAD 
and concomitant AIT that are associated with reduced transcriptional activity of NF-kB. 
Keywords: resveratrol, coronary artery disease, autoimmune thyroiditis, chronic 
systemic inflammation, NF-kB. 
 
ПРОТИВОВЪЗПАЛИТЕЛНИТЕ ЕФЕКТИ НА РЕСВЕРАТРОЛ СЪС 
СТАБИЛНА ИСХЕМИЧНА БОЛЕСТ НА СЪРЦЕТО В СЪЧЕТАНИЕ С 
АВТОИМУНЕН ТИРЕОИДИТ 
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Резюме 
Целта на проучването е да се изследва ефекта на ресвератрол върху маркери на 
хронично системно възпаление при пациенти с исхемична болест на сърцето 
(CHD) във връзка с автоимунно тиреоидит (тиреоидит на Хашимото). В 
изследването са участвали 85 пациенти с исхемична болест на сърцето: ангина, 
стабилно напрежение, FC II, 30 от които имаше допълнителна диагностика на 
тиреоидит (проучвателна група) на Хашимото, тиреоиден опция, 55 пациенти, 
направени от групата сравнение. След един месец за стабилизиране CHD 
терапия (бета-блокери, статини, аспирин), при пациенти определяне нивата на 
интерлевкин-1β кръвта (IL-1β), IL-10, тумор некрозен фактор (TNF-α) и 
експресия на ген мРНК инхибитор капа В (IkB ) ядрен транскрипционен фактор 
kB (NF-kB). След това групата на проучване допълнително назначен 
ресвератрол в доза от 100 мг на ден и 2 месеца са повтори проучвания. ИБС 
пациенти в комбинация с повишени нива на AIT намерени IL-1β, TNF-α, IL-
умерено повишаване на 10, данните не са значително различни от резултатите 
на контролната група. Експресията на мРНК IkB е идентичен и в двете групи. 
Под влиянието на ресвератрол при пациенти с нива на изследването IL-1β, 
TNF-α значително намалява нивото на IL-10 не се променя експресията на 
мРНК IkBα намалява (р <0,05), в сравнение, тези показатели не са се променили 
група. Тези резултати показват, противовъзпалителните свойства на 
ресвератрол в комбинация с CHD AIT, свързани с намалена транскрипционна 
активност на NF-кВ. 
Ключови думи: ресвератрол, исхемична болест на сърцето, автоимунен 
тиреоидит, хроничен системно възпаление, NF-КВ. 
 
Introduction 
Coronary artery disease (CAD) has remained one of the leading causes of death 
throughout the world [3]. The incidence of endocrine disorders is also reported to be 
increasing significantly, and thyroid diseases make up their largest part. In Ukraine, 
the prevalence of autoimmune thyroiditis (AIT) known as the underlying cause of 
hypothyroidism has increased by 68% over the past decade [4]. Rising stress level, 
environmental pollution, poor nutrition is considered as primary causes of the disease 
and underlies the doleful statistics. Increasingly, there is a problem of controlling and 
managing the comorbidities. 
According to relevant research data, the development and progression of 
atherosclerosis regarded as the morphological basis of CAD is strongly associated 
with chronic systemic inflammation (CSI), which is also known to play a leading role 
in the pathogenesis of autoimmune thyroiditis.      
A lack of CD4+CD25+ regulatory T cells described in both pathological 
conditions above mentioned is the main cause resulting in insufficient suppression of 
inflammation. Both processes are characterized by presence of dendritic cells in the 
affected area of the antigen forming molecules of major histocompatibility complex, 
by impaired selection of CD4 + T killer cells, which then develop autoagressive 
characteristics and B-cell response with the synthesis of autoantibodies [8, 9]. 
However, the main factor resulting in the impairment in both CAD and AIT is 
cytokines (CK) released during the activation of immune and other cells involved in 
the disease process that mediate the cellular interactions. Cytokines are the main 
transmitters of inflammation signal transduction, activating cascades that mediate the 
formation of adhesion molecules, chemoattractant compounds, growth factors, and 
closing the "vicious circle" of inflammation [6, 8]. Cytokines can also potentiate 
apoptosis of activated cells. It is well established that in the condition of AIT 30% of 
thyrocytes undergo apoptosis. The antibodies in the pathogenesis of AIT according to 
recent reports are of less pathogenic significance, being described mostly as markers 
of the disease they do not determine the intensity of its course and its prognosis [15]. 
The thoughts hereinabove explained require elaborating general 
pathogenetically reasonable approaches to the management of CAD and AIT, and 
particularly by influencing CSI.  
The aim of this research was to study the influence produced by resveratrol, a 
polyphenol antioxidant, on the level of systemic inflammation in patients with 
coronary artery disease and concomitant autoimmune thyroiditis.  
Materials and methods 
The study involved 85 patients aged 48-67 with CAD, stable exertional angina 
class II 0 CH-I, 30 of whom diagnosed to have AIT, its euthyroid state, made up the 
experimental group, the rest 55 patients were assigned to the control group. Diagnosis 
of CAD was established in accordance with the standards of the European Society of 
Cardiologists, 2013, the diagnosis of AIT was made based on standards set by 
European Thyroid Association, 2013 [11, 16]. Exclusion criteria were hypertension 
stage II above, rheumatism, diabetes, chronic liver and kidney diseases, 
musculoskeletal inflammatory diseases in the acute stage, cancerous diseases. All the 
patients gave written informed consent to participate in the study, as required by the 
Helsinki Declaration, 1975. According to laboratory investigations, 5 patients were 
diagnosed to have subclinical hypothyroidism, and 2 patients had hypothyroidism. 
The day prior the inclusion in the test group the patients achieved euthyroid state by 
taking proper doses of L-thyroxine (25-75 mg daily). 
In order to stabilize the clinical course all the patients were prescribed the 
standard CAD therapy: beta-blockers (bisoprolol, 5-10 mg per day), statins 
(atorvastatin, 10 mg daily), aspirin (100 mg per day). Short-acting nitrates (isosorbide 
dinitrate) were taken by the patients when necessary. According to the clinical 
guidelines, in cases of euthyroid AIT no treatment was carried out. 
One month since the beginning of stabilization therapy all the participants 
passed through laboratory studies including evaluation of blood serum cytokines: 
interleukin-1β (IL-1β), tumour necrosis factor α (TNF-α) and IL-10 by ELISA using 
test-system "Vector-Best" (Novosibirsk, Russia) that was based on sandwich solid-
phase ELISA with using mono- and polyclonal antibodies [1]. We also assessed the 
gene expression inhibitor of nuclear factor-kappa B α (IkBα) nuclear factor 
transctiption kB (NF-kB) in peripheral blood mononuclear cells by polymerase chain 
reaction in real time (Real-time PCR) using a thermocyclers DT Light ("DNA 
Technology", Russia) [12]. To obtain cDNA we used a set of reagents for the reaction 
of inverse transcription (SYNTHOL, Russia). The total RNA was isolated from 
biological sample using a reagents kit "Rybo-sol-B» (AmpliSens, Russia). The 
sequence of primers for determining gene expression IkBα - F: 5 '- GGC TGA AGA 
AGG AGC GGC TA - 3', R: 5 '- CCA TCT GCT CGT ACT CCT CG -3'. 
Amplification mode: 95.0 - 5 minutes - 1 cycle; 62.0 - 40 seconds, 95.0 - 15 seconds - 
40 cycles. As a reference gene we used a housekeeping   gene GAPDH. The 2
-
ΔΔCT
 and 2
-∆Сt 
methods were used as a relative quantification strategy for quantitative 
real-time polymerase chain reaction data analysis.  
Having passed the examination described above, the patients of the 
experimental group were prescribed to take resveratrol in a single oral dose of 100 
mg per day in addition to conventional therapy. The control group took the course of 
conventional treatment. The results of treatment were evaluated in 2 months by re-
examining the patients of both groups. During the examination and treatment patients 
had no complications, allergic reactions and hypersensitive to medicines. 
Statistical processing of the findings obtained was carried out by the licensed 
program KyPlot. The assumption that the data followed a normal distribution was 
checked by Shapiro–Wilk test. To compare the findings of patients’ examinations 
before and after the course of therapy paired Student t-test was used, in cases of 
abnormal distribution non-parametric paired Wilcoxon test was performed as well as 
the Still-test was used for paired observations. To compare data between the groups 
we performed unpaired Student t-test and Steel-Dwass test (nonparametric analogue 
of Tukey’s test). Data of statistical analysis were presented in the form of X + σ, 
where X was the average value, σ was the standard deviation. On the assumption of 
misdistribution and signs of discontinuous series the data were given as Me (Q1-Q3), 
where Me – median, Q1 and Q3 - upper and lower quartiles. Differences between the 
results were regarded as significant when the significance threshold was kept 
at p < 0.05. 
 
Results 
The patients with CAD and comorbid AIT demonstrated elevated levels of 
cytokines (p <0.05) (Table 1). In the healthy individuals IL-1β equalled 1.6 
(percentile interval - 0-11) pg/ml, TNF-α — 0,5 (0-6) pg/ml, IL-10 — 5 (0-31) pg/ml 
[5]. The control group also demonstrated increased cytokines under the study (Table 
1). No significant difference between the values of the groups compared was found 
(p> 0.05). 
In 2 months after the completion of the therapy including resveratrol the 
patients with CAD and concomitant AIT were observed to have significantly 
decreased levels of IL-1β and TNF-α, while there were no significant changes in the 
level of IL-10. The control group tended to decrease IL-1β and IL-10, but differences 
in values before and after the therapy were not significant (p> 0.05) (Table 1). 
Table 1 
Cytokines levels in the blood serum of the subjects of the study 
 
          Note: X – the sample mean, σ – standard deviation, p – probability. 
 
 
The patients with CAD and those who had CAD and concomitant AIT 
demonstrated no significant difference (p> 0.05) in the levels of mRNA IkBα gene 
expression in blood mononuclear cells. Presumably due to the effect of resveratrol the 
patients showed significantly decreased (p = 0.003) mRNA IkBα gene expression in 
contrast to the results obtained in the control group (Table 2). 
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Control   
group 
CAD 
Х 
σ 
8,53 
+3,24 
8,34 
+2,17 
9,46 
+2,98 
7,16 
+2,98 
10,51+
3,33 
8,72 
+3,51 
р = 0,866 р = 0,127 р = 0,134 
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group 
CAD+АІТ 
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10,54 
+2,42 
7,94 
+3,43 
10,06+
2,79 
6,87 
+2,13 
10,08+
3,99 
9,19 
+2,68 
р = 0,0005 р = 0,0011 р = 0,455 
Table 2 
Level of mRNA IkBα expression in peripheral blood mononuclear cells of 
the subjects of the study 
 
 
Note: X – the sample mean, σ –  standard quadratic deviation,  
         * – Wilcocson (U), significant differences with the data of all groups. 
 
Discussion 
The results obtained reported the intensity of chronic systemic inflammation in 
stable CAD and concomitant AIT in its euthyroid state did not differ significantly 
from that in separate stable CAD that was assessed by the level of NF-kB 
transcriptional activity and by the direct result of its increase, i.e. cytokines 
production. 
However, we found out the fact of increase in chronic systemic inflammation. 
Perhaps, the lack of prevalence was determined by the moderate systemic 
inflammation in stable CAD. In turn, euthyroid state indirectly reflects moderate 
autoimmune thyroid inflammation as at high rate chronic systemic inflammation 
apoptosis of thyrocytes becomes more intense followed by loss of functional activity 
of the thyroid gland. 
It is known that the increase in signal transduction involving NF-kB occurs via 
appropriate ligand receptors IL-1β, TNF-α, Toll-like receptors, CD 32, CD 40, CD 64 
and others [2]. Moreover, the enhancement of pro-inflammatory signalling may result 
in the production of inflammatory molecules by means of activating protein-1 (AP-
1). Signaling pathways involve numerous proteases and cofactors required for their 
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+0,0062 
- 2,016*                           
(-4,5 - +2,83) 
р=0,570       р=0,031 
functioning and are pluripotent. Signalling by MAP kinase pathway (MAR - protein 
kinase that is activated by myogenes) results in the increase of expression of c-Fos 
and c-Myc genes that mediate the induction of apoptosis [10]. 
Reduction in the level of pro-inflammatory cytokines as IL-1β and TNF-α due 
to resveratrol is the evidence of its effect produced on NF-kB, the main factor 
responsible for their production [14]. This conclusion is supported in our study by 
decreased mRNA IkBα expression in blood mononuclear cells. The lack of effect 
produced by resveratrol on IL-10 can be explained by analyzing the signaling 
pathways of its formation. The same inflammatory stimuli acting on the intermediate 
transcription TNF-α-associated factor 6 (TRAF6) activate both NF-kB and AP-1 
signaling [7]. This leads to increased transcription of IL-10 that is demonstrated in 
our study. However, inactivation of NF-kB does not exclude the AP-1 transcriptional 
activity that, in our opinion, has caused permanent moderately elevated levels of IL-
10, which have anti-inflammatory properties of projective value. 
Despite a lot of reports supporting information on the anti-inflammatory 
efficacy of statins that the patients took as a component of the standard therapy, we 
found out no evidence of this in our study. We can assume that statins should be 
taken over longer period of time to implement their pleiotropic effects, and a dose of 
atorvastatin (10 mg per day) we chose needs further titration to achieve optimal 
efficacy. 
Anti-inflammatory activity of resveratrol we observed in our study can be 
explained by its effect on different molecular levels of cell organization. With three 
hydroxyl groups, resveratrol inactivates free radicals, which play a significant role in 
cell activation. Resveratrol enhances the activity of superoxide dismutase, catalase 
and glutathione enzyme systems, inhibits cyclooxygenase and lipoxygenase at post-
transcriptional level [17]. Our findings on the ability of resveratrol to block 
transcriptional activity of NF-kB agree with available relevant research data [14].   
Resveratrol blocks IkB-kinase, which got activated by various pro-
inflammatory stimuli, destroys the relationship between NF-kB (p50 / R65) and IkBα 
that leads to the translocation of subunit R65 in the nucleus and activates the 
transcription of pro-inflammatory genes. It has also been demonstrated that 
resveratrol acts as an activator gene sirtuin-1 (SIRT1), which supports mitochondrial 
metabolism and piston framework density preventing the pathogenic gene 
transcription. Recent scientific studies have found that SIRT1 diacetylates subunit 
p65 by Lys 310 residue by weakening the NF-κB-signaling [13]. 
Conclusions  
Thus, the patients with stable coronary artery disease as well as the patients 
with coronary artery disease and concomitant autoimmune thyroiditis in its euthyroid 
state demonstrate marked increase in the level of chronic systemic inflammation 
without any significant prevalence. 
Two month course of resveratrol therapy significantly reduced the level of 
systemic inflammation in the patients with coronary artery disease and comorbid 
autoimmune thyroiditis by reducing the transcriptional activity of NF-κB, and 
presumably by getting involved other numerous mechanisms of its projective action. 
Atorvastatin in a dose of 10 mg per day for two month course was found out to 
produce no pleiotropic anti-inflammatory effect in coronary artery disease. 
The anti-inflammatory activity of resveratrol regarded as a component of 
standard statin therapy of coronary artery disease determines the expediency of 
combining   these agents in the condition studied that increases the effectiveness and 
safety profile of medication in cases when high doses of statins can be administered.  
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Таблица 1 
Концентрацията на цитокини в серума на пациенти с изследователски 
групи 
Забележки:   X - средна стойност, σ - стандартното отклонение, 
                       р - вероятност. 
 
Таблица 2 
Нивото на експресия на мРНК IkBα в периферни кръвни мононуклеарни 
клетки на пациенти с изследователски групи 
Забележки:   X - средна стойност, σ - стандартното отклонение, 
                       р – вероятност, * - cъществена разлика с тези на всички групи 
                       изследвания преди и след лечението (р <0,01). 
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